Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response?
作者信息
Zarychanski Ryan, Houston Donald S
机构信息
Section of Hematology/Medical Oncology, Department of Internal Medicine, University of Manitoba, Winnipeg, Man.
出版信息
CMAJ. 2008 Aug 12;179(4):333-7. doi: 10.1503/cmaj.071131.
Abstract
摘要
相似文献
1
Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response?
CMAJ. 2008 Aug 12;179(4):333-7. doi: 10.1503/cmaj.071131.
2
Erythropoietin pathophysiology and erythropoietin deficiency anemia.
Hematol J. 2004;5 Suppl 3:S100-3. doi: 10.1038/sj.thj.6200432.
3
Does TREAT give the boot to ESAs in the treatment of CKD anemia?
J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24.
4
Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both? Editorial to: "Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by Pappas et al.".
Cardiovasc Drugs Ther. 2008 Feb;22(1):1-2. doi: 10.1007/s10557-008-6079-x.
5
Erythropoietin to treat anaemia in patients with head and neck cancer.
Lancet. 2004 Jan 3;363(9402):80-1; author reply 81-2. doi: 10.1016/S0140-6736(03)15186-0.
6
Guidelines for the use of recombinant human erythropoietin.
Haematologica. 1994 Nov-Dec;79(6):526-33.
7
Breast cancer trial with erythropoietin terminated unexpectedly.
Lancet Oncol. 2003 Aug;4(8):459-60. doi: 10.1016/s1470-2045(03)01163-x.
8
Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
Nephrol Dial Transplant. 2009 Apr;24(4):1082-8. doi: 10.1093/ndt/gfn601. Epub 2008 Nov 5.
9
Erythropoietin: high profile, high scrutiny.
J Clin Oncol. 2007 Mar 20;25(9):1021-3. doi: 10.1200/JCO.2006.08.8153. Epub 2007 Feb 20.
10
Hypothesis versus association: the optimal hemoglobin target debate.
Am J Kidney Dis. 2005 Nov;46(5):970-3. doi: 10.1053/j.ajkd.2005.09.009.
引用本文的文献
1
Session 4: mRNA and Self-Amplifying RNA (saRNA): Opportunities for Disease Prevention and Therapy.
Toxicol Pathol. 2024 Dec;52(8):545-552. doi: 10.1177/01926233241298572. Epub 2024 Nov 22.
2
A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
Korean J Intern Med. 2024 May;39(3):488-500. doi: 10.3904/kjim.2023.520. Epub 2024 Apr 23.
3
Prevalence of Anemia in Pediatric Patients According to Asthma Control: Propensity Score Analysis.
J Asthma Allergy. 2021 Jun 29;14:743-751. doi: 10.2147/JAA.S318641. eCollection 2021.
4
Iron Fortification and Supplementation: Fighting Anemia of Chronic Diseases or Fueling Obesity?
Curr Dev Nutr. 2021 Apr 7;5(4):nzab032. doi: 10.1093/cdn/nzab032. eCollection 2021 Apr.
5
Treatment of anemia in difficult-to-manage patients with chronic kidney disease.
Kidney Int Suppl (2011). 2021 Apr;11(1):26-34. doi: 10.1016/j.kisu.2020.12.006. Epub 2021 Mar 18.
6
The magnitude of anemia and associated factors among adult diabetic patients in Tertiary Teaching Hospital, Northern Ethiopia, 2019, cross-sectional study.
PLoS One. 2020 Nov 10;15(11):e0240678. doi: 10.1371/journal.pone.0240678. eCollection 2020.
7
The Role of Blood Viscosity in Infectious Diseases.
Cureus. 2020 Feb 24;12(2):e7090. doi: 10.7759/cureus.7090.
8
Prevalence of Anemia and Associated Factors among Newly Diagnosed Patients with Solid Malignancy at Tikur Anbessa Specialized Hospital, Radiotherapy Center, Addis Ababa, Ethiopia.
Adv Hematol. 2019 Oct 20;2019:8279789. doi: 10.1155/2019/8279789. eCollection 2019.
9
Ferritin in Kidney and Vascular Related Diseases: Novel Roles for an Old Player.
Pharmaceuticals (Basel). 2019 Jun 21;12(2):96. doi: 10.3390/ph12020096.
10
Early Blood Profile of C57BL/6 Mice Exposed to Chronic Unpredictable Stress.
Front Psychiatry. 2019 Apr 24;10:230. doi: 10.3389/fpsyt.2019.00230. eCollection 2019.
本文引用的文献
1
STUDIES OF OXYGEN IN THE VENOUS BLOOD : V. DETERMINATIONS ON PATIENTS WITH ANEMIA.
J Exp Med. 1919 Aug 1;30(2):147-58. doi: 10.1084/jem.30.2.147.
2
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
JAMA. 2008 Feb 27;299(8):914-24. doi: 10.1001/jama.299.8.914.
3
Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials.
CMAJ. 2007 Sep 25;177(7):725-34. doi: 10.1503/cmaj.071055. Epub 2007 Sep 5.
4
Efficacy and safety of epoetin alfa in critically ill patients.
N Engl J Med. 2007 Sep 6;357(10):965-76. doi: 10.1056/NEJMoa071533.
5
Impact of blood transfusions in patients presenting with anemia and suspected acute coronary syndrome.
Am J Cardiol. 2007 Apr 15;99(8):1119-21. doi: 10.1016/j.amjcard.2006.11.056. Epub 2007 Feb 21.
6
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
J Clin Oncol. 2007 Mar 20;25(9):1027-32. doi: 10.1200/JCO.2006.07.1514. Epub 2007 Feb 20.
7
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.
Lancet. 2007 Feb 3;369(9559):381-8. doi: 10.1016/S0140-6736(07)60194-9.
8
Correction of anemia with epoetin alfa in chronic kidney disease.
N Engl J Med. 2006 Nov 16;355(20):2085-98. doi: 10.1056/NEJMoa065485.
9
Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
N Engl J Med. 2006 Nov 16;355(20):2071-84. doi: 10.1056/NEJMoa062276.
10
THE CARDIAC OUTPUT IN PATIENTS WITH CHRONIC ANEMIA AS MEASURED BY THE TECHNIQUE OF RIGHT ATRIAL CATHETERIZATION.
J Clin Invest. 1945 May;24(3):332-6. doi: 10.1172/JCI101610.
Zotero 插件